Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Accumulated Expenses (2017 - 2026)

Anika Therapeutics has reported Other Accumulated Expenses over the past 15 years, most recently at $479000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 38.27% to $479000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $479000.0 through Mar 2026, down 38.27% year-over-year, with the annual reading at $468000.0 for FY2025, 38.82% down from the prior year.
  • Other Accumulated Expenses was $479000.0 for Q1 2026 at Anika Therapeutics, up from $468000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $1.1 million in Q1 2022 and troughed at $338000.0 in Q4 2023.
  • The 5-year median for Other Accumulated Expenses is $517000.0 (2024), against an average of $611941.2.
  • Year-over-year, Other Accumulated Expenses plummeted 97.14% in 2022 and then surged 126.33% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $510000.0 in 2022, then plummeted by 33.73% to $338000.0 in 2023, then skyrocketed by 126.33% to $765000.0 in 2024, then crashed by 38.82% to $468000.0 in 2025, then grew by 2.35% to $479000.0 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Other Accumulated Expenses are $479000.0 (Q1 2026), $468000.0 (Q4 2025), and $750000.0 (Q3 2025).